Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

444 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.
Rheault MN, Alpers CE, Barratt J, Bieler S, Canetta P, Chae DW, Coppock G, Diva U, Gesualdo L, Heerspink HJL, Inrig JK, Kirsztajn GM, Kohan D, Komers R, Kooienga LA, Lieberman K, Mercer A, Noronha IL, Perkovic V, Radhakrishnan J, Rote W, Rovin B, Tesar V, Trimarchi H, Tumlin J, Wong MG, Trachtman H; DUPRO Steering Committee and DUPLEX Investigators. Rheault MN, et al. Among authors: barratt j. N Engl J Med. 2023 Dec 28;389(26):2436-2445. doi: 10.1056/NEJMoa2308550. Epub 2023 Nov 3. N Engl J Med. 2023. PMID: 37921461 Clinical Trial.
A Multicenter Study of the Predictive Value of Crescents in IgA Nephropathy.
Haas M, Verhave JC, Liu ZH, Alpers CE, Barratt J, Becker JU, Cattran D, Cook HT, Coppo R, Feehally J, Pani A, Perkowska-Ptasinska A, Roberts IS, Soares MF, Trimarchi H, Wang S, Yuzawa Y, Zhang H, Troyanov S, Katafuchi R. Haas M, et al. Among authors: barratt j. J Am Soc Nephrol. 2017 Feb;28(2):691-701. doi: 10.1681/ASN.2016040433. Epub 2016 Sep 9. J Am Soc Nephrol. 2017. PMID: 27612994 Free PMC article.
Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial.
Fellström BC, Barratt J, Cook H, Coppo R, Feehally J, de Fijter JW, Floege J, Hetzel G, Jardine AG, Locatelli F, Maes BD, Mercer A, Ortiz F, Praga M, Sørensen SS, Tesar V, Del Vecchio L; NEFIGAN Trial Investigators. Fellström BC, et al. Among authors: barratt j. Lancet. 2017 May 27;389(10084):2117-2127. doi: 10.1016/S0140-6736(17)30550-0. Epub 2017 Mar 28. Lancet. 2017. PMID: 28363480 Clinical Trial.
Identifying Outcomes Important to Patients with Glomerular Disease and Their Caregivers.
Carter SA, Gutman T, Logeman C, Cattran D, Lightstone L, Bagga A, Barbour SJ, Barratt J, Boletis J, Caster D, Coppo R, Fervenza FC, Floege J, Hladunewich M, Hogan JJ, Kitching AR, Lafayette RA, Malvar A, Radhakrishnan J, Rovin BH, Scholes-Robertson N, Trimarchi H, Zhang H, Azukaitis K, Cho Y, Viecelli AK, Dunn L, Harris D, Johnson DW, Kerr PG, Laboi P, Ryan J, Shen JI, Ruiz L, Wang AY, Lee AHK, Fung S, Tong MK, Teixeira-Pinto A, Wilkie M, Alexander SI, Craig JC, Tong A; SONG-GD Investigators. Carter SA, et al. Among authors: barratt j. Clin J Am Soc Nephrol. 2020 May 7;15(5):673-684. doi: 10.2215/CJN.13101019. Epub 2020 Apr 30. Clin J Am Soc Nephrol. 2020. PMID: 32354728 Free PMC article.
Improving treatment decisions using personalized risk assessment from the International IgA Nephropathy Prediction Tool.
Barbour SJ, Canney M, Coppo R, Zhang H, Liu ZH, Suzuki Y, Matsuzaki K, Katafuchi R, Induruwage D, Er L, Reich HN, Feehally J, Barratt J, Cattran DC; International IgA Nephropathy Network. Barbour SJ, et al. Among authors: barratt j. Kidney Int. 2020 Oct;98(4):1009-1019. doi: 10.1016/j.kint.2020.04.042. Epub 2020 May 25. Kidney Int. 2020. PMID: 32464215
Why Target the Gut to Treat IgA Nephropathy?
Barratt J, Rovin BH, Cattran D, Floege J, Lafayette R, Tesar V, Trimarchi H, Zhang H; NefIgArd Study Steering Committee. Barratt J, et al. Kidney Int Rep. 2020 Aug 20;5(10):1620-1624. doi: 10.1016/j.ekir.2020.08.009. eCollection 2020 Oct. Kidney Int Rep. 2020. PMID: 33102954 Free PMC article. No abstract available.
444 results